We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Adverum Biotechnologies Inc | NASDAQ:ADVM | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.43 | 4.30% | 10.43 | 9.75 | 44.43 | 10.69 | 10.00 | 10.10 | 900,531 | 05:00:01 |
Delaware
|
001-36579
|
20-5258327
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)
|
☐
|
Pre-commencement communication pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock
|
ADVM
|
Nasdaq Global Market
|
Emerging growth company
|
☐
|
Item 8.01
|
Other Events.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
99.1 |
Press Release dated April 28, 2021, providing an update on Adverum Biotechnologies, Inc.’s INFINITY trial evaluating ADVM-022 in patients with diabetic macular edema.
|
104 |
Cover Page Interactive Data File (formatted as Inline XBRL and included in Exhibit 101)
|
Adverum Biotechnologies, Inc.
|
||
Date: April 28, 2021
|
By:
|
/s/ Laurent Fischer, M.D.
|
Laurent Fischer, M.D.
|
||
Chief Executive Officer
|
1 Year Adverum Biotechnologies Chart |
1 Month Adverum Biotechnologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions